Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

First low-dose hydrochlorothiazide product approvable

Oct. 18, 1996

Antihypertensive combination cleared for marketing in the U.S.

Oct. 18, 1996

PRAISE trial demonstrates safety of calcium channel blocker in severe heart failure

Oct. 18, 1996

Significant progress in cardiovascular R&D at Yamanouchi

Oct. 11, 1996

BTG licenses drug for cardiac arrest

Oct. 11, 1996

New approval for carvedilol in congestive heart failure

Oct. 11, 1996

Clinical results with adenosine agonist

Oct. 11, 1996

Lynx licenses antisense compound for restenosis to Schwarz

Oct. 11, 1996

New antioxidant for atherosclerosis

Oct. 11, 1996

MTP inhibitors from Bristol-Myers Squibb

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...